21 May 2013
Keywords: strong, ph, ii, results, celtic, nail, fungus
Article | 30 March 2009
US drugmaker Celtic Pharmaceutical has reported the successful outcome of its Phase II trial of TDT-067 (terbinafine in Transfersomes), for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
16 February 2009
20 May 2013
© 2013 thepharmaletter.com